.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PARADIGMS randomized phase 3 trial compared fingolimod with intramuscular interferon beta-1a in children and adolescents aged 10 to under 18 years with multiple sclerosis. Fingolimod produced a substantially lower annualized relapse rate and fewer new or newly enlarged T2 lesions. Benefits were also observed in treatment-naive and younger subgroups. The findings are clinically important because childhood-onset MS can be highly inflammatory, and recurrent relapses may contribute to disability and cognitive burden during a vulnerable developmental period. The study provides evidence that a high-efficacy oral disease-modifying therapy can control pediatric MS more effectively than interferon. For HCPs, treatment selection still needs to account for infection risk, vaccination, adherence, monitoring requirements and the child's developmental context. Fingolimod also carries specific cardiac and ophthalmic precautions. The broader lesson is that paediatric MS should not automatically be treated as a milder version of adult disease; early disease control can be important for preserving neurological and developmental function. This directly complements IANCON's emphasis on precision and future-oriented MS care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PARADIGMS randomized phase 3 trial compared fingolimod with intramuscular interferon beta-1a in children and adolescents aged 10 to under 18 years with multiple sclerosis. Fingolimod produced a substantially lower annualized relapse rate and fewer new or newly enlarged T2 lesions. Benefits were also observed in treatment-naive and younger subgroups. The findings are clinically important because childhood-onset MS can be highly inflammatory, and recurrent relapses may contribute to disability and cognitive burden during a vulnerable developmental period. The study provides evidence that a high-efficacy oral disease-modifying therapy can control pediatric MS more effectively than interferon. For HCPs, treatment selection still needs to account for infection risk, vaccination, adherence, monitoring requirements and the child's developmental context. Fingolimod also carries specific cardiac and ophthalmic precautions. The broader lesson is that paediatric MS should not automatically be treated as a milder version of adult disease; early disease control can be important for preserving neurological and developmental function. This directly complements IANCON's emphasis on precision and future-oriented MS care.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
